{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:01:31Z","timestamp":1768590091308,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI104441"],"award-info":[{"award-number":["R21AI104441"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI102639"],"award-info":[{"award-number":["K23AI102639"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/jac\/dkx111","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T15:11:54Z","timestamp":1491837114000},"page":"2020-2027","source":"Crossref","is-referenced-by-count":8,"title":["Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB"],"prefix":"10.1093","volume":"72","author":[{"given":"Christopher","family":"Vinnard","sequence":"first","affiliation":[{"name":"Public Health Research Institute, Rutgers, The State University of New Jersey, 225 Warren Street, Newark, NJ 07103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruthi","family":"Ravimohan","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neo","family":"Tamuhla","sequence":"additional","affiliation":[{"name":"Botswana-UPenn Partnership, 214 Independence Avenue, Gaborone, Botswana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jotam","family":"Pasipanodya","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, 3434 Live Oak Street, Dallas, TX 75204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, 3434 Live Oak Street, Dallas, TX 75204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chawangwa","family":"Modongo","sequence":"additional","affiliation":[{"name":"Botswana-UPenn Partnership, 214 Independence Avenue, Gaborone, Botswana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola M.","family":"Zetola","sequence":"additional","affiliation":[{"name":"Botswana-UPenn Partnership, 214 Independence Avenue, Gaborone, Botswana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, 3434 Live Oak Street, Dallas, TX 75204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Bisson","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"key\n\t\t\t\t20180313122716_dkx111-B1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/651686","article-title":"Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis","volume":"50","author":"Khan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/318706","article-title":"A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes","volume":"32","author":"El-Sadr","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/375220","article-title":"Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review","volume":"37","author":"Korenromp","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B4","first-page":"455","article-title":"The impact of HIV infection on recurrence of tuberculosis in South African gold miners","volume":"4","author":"Mallory","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B5","author":"WHO","year":"2010"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B6","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B7","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600\u2009mg of rifampin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B8","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","article-title":"Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection","volume":"127","author":"Sahai","year":"1997","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B10","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/498024","article-title":"The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis","volume":"41","author":"Perlman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ni1316","article-title":"HIV disease: fallout from a mucosal catastrophe?","volume":"7","author":"Brenchley","year":"2006","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/QAD.0b013e3280142ee8","article-title":"HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV\/Microsporidia-infected jejunal mucosa","volume":"21","author":"Batman","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002030-200501280-00002","article-title":"HIV infection and the gastrointestinal tract","volume":"19","author":"Kotler","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1086\/590112","article-title":"Collagen deposition limits immune reconstitution in the gut","volume":"198","author":"Estes","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/imr.12065","article-title":"Immune activation and HIV persistence: implications for curative approaches to HIV infection","volume":"254","author":"Klatt","year":"2013","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/655229","article-title":"Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy","volume":"202","author":"Cassol","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B19","first-page":"904","article-title":"Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6\u2009years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study","volume":"6","author":"Giorgi","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","article-title":"Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression","volume":"16","author":"Liu","year":"1997","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/bcp.13172","article-title":"Isoniazid clearance is impaired among HIV\/tuberculosis patients with high levels of immune activation","volume":"83","author":"Vinnard","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B22","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","article-title":"Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease","volume":"48","author":"Gurumurthy","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1413-86702006000600003","article-title":"Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis","volume":"10","author":"Pinheiro","year":"2006","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1590\/S1413-86702009000300011","article-title":"Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis","volume":"13","author":"Facanha","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4269\/ajtmh.2009.81.322","article-title":"Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis","volume":"81","author":"Barroso","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B27","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B28","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.02307-13","article-title":"Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV","volume":"58","author":"Jeremiah","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/civ978","article-title":"Robust reconstitution of TB-specific polyfunctional CD4+ T cell responses and rising systemic IL-6 in paradoxical TB-IRIS","volume":"62","author":"Ravimohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpb.b14-00767","article-title":"Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs","volume":"38","author":"Maeda","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B31","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B32","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/AAC.01833-10","article-title":"The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications","volume":"55","author":"Chigutsa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/0470087978","volume-title":"Pharmacometrics: The Science of Quantitative Pharmacology","author":"Ette","year":"2007"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B34","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1128\/AAC.02051-15","article-title":"Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa","volume":"60","author":"Denti","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B37","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1128\/AAC.01193-15","article-title":"Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi","volume":"59","author":"van Oosterhout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B39","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jac\/dkr445","article-title":"Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso","volume":"67","author":"Saleri","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B41","author":"Utay"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B42","doi-asserted-by":"crossref","first-page":"e81856.","DOI":"10.1371\/journal.pone.0081856","article-title":"LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients","volume":"8","author":"Goovaerts","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180313122716_dkx111-B43","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.05792-11","article-title":"A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients","volume":"56","author":"Smythe","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/7\/2020\/24332453\/dkx111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:53:59Z","timestamp":1569002039000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/7\/2020\/3788899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,5,2]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx111","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,5,2]]}}}